2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Treatment capacity required for full‐scale implementation of lung cancer screening in the United States

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Full‐scale implementation of lung cancer screening in the United States will increase detection of early stages. This study was aimed at assessing the capacity required for treating those cancers.

          Methods

          A well‐established microsimulation model was extended with treatment data from the National Cancer Database. We assessed how treatment demand would change when implementing lung cancer screening in 2018. Three policies were assessed: 1) annual screening of current smokers and former smokers who quit fewer than 15 years ago, aged 55 to 80 years, with a smoking history of at least 30 pack‐years (US Preventive Services Task Force [USPSTF] recommendations); 2) annual screening of current smokers and former smokers who quit fewer than 15 years ago, aged 55 to 77 years, with a smoking history of at least 30 pack‐years (Centers for Medicare and Medicaid Services [CMS] recommendations); and 3) annual screening of current smokers and former smokers who quit fewer than 10 years ago, aged 55 to 75 years, with a smoking history of at least 40 pack‐years (the most cost‐effective policy in Ontario [Ontario]). The base‐case screening adherence was a constant 50%. Sensitivity analyses assessed other adherence levels, including a linear buildup to 50% between 2018 and 2027.

          Results

          The USPSTF policy would require 37.0% more lung cancer surgeries in 2015‐2040 than no screening, 2.2% less radiotherapy, and 5.4% less chemotherapy; 5.7% more patients would require any therapy. The increase in surgical demand would be 96.1% in 2018, 46.0% in 2023, 38.3% in 2028, and 24.9% in 2040. Adherence strongly influenced results. By 2018, surgical demand would range from 52,619 (20% adherence) to 96,121 (80%). With a gradual buildup of adherence, the increase in surgical demand would be 9.6% in 2018, 38.3% in 2023, 42.0% in 2028, and 24.4% in 2040. Results for the CMS and Ontario policies were similar, although the changes in comparison with no screening were smaller.

          Conclusions

          Full‐scale implementation of lung cancer screening causes a major increase in surgical demand, with a peak within the first 5 years. A gradual buildup of adherence can spread this peak over time. Careful surgical capacity planning is essential for successfully implementing screening.

          Abstract

          Full‐scale implementation of lung cancer screening in the United States will lead to a major increase in the demand for thoracic surgery. Careful surgical capacity planning is essential for successfully implementing screening.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: not found
          Is Open Access

          The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups.

          Lung cancer is the leading cause of cancer death in North America. Low-dose computed tomography screening can reduce lung cancer-specific mortality by 20%. The American Association for Thoracic Surgery created a multispecialty task force to create screening guidelines for groups at high risk of developing lung cancer and survivors of previous lung cancer. The American Association for Thoracic Surgery guidelines call for annual lung cancer screening with low-dose computed tomography screening for North Americans from age 55 to 79 years with a 30 pack-year history of smoking. Long-term lung cancer survivors should have annual low-dose computed tomography to detect second primary lung cancer until the age of 79 years. Annual low-dose computed tomography lung cancer screening should be offered starting at age 50 years with a 20 pack-year history if there is an additional cumulative risk of developing lung cancer of 5% or greater over the following 5 years. Lung cancer screening requires participation by a subspecialty-qualified team. The American Association for Thoracic Surgery will continue engagement with other specialty societies to refine future screening guidelines. The American Association for Thoracic Surgery provides specific guidelines for lung cancer screening in North America. Copyright © 2012. Published by Mosby, Inc.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Implementation of Lung Cancer Screening in the Veterans Health Administration.

            The US Preventive Services Task Force recommends annual lung cancer screening (LCS) with low-dose computed tomography for current and former heavy smokers aged 55 to 80 years. There is little published experience regarding implementing this recommendation in clinical practice.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Patterns of birth cohort-specific smoking histories, 1965-2009.

              Characterizing the smoking patterns for different birth cohorts is essential for evaluating the impact of tobacco control interventions and predicting smoking-related mortality, but the process of estimating birth cohort smoking histories has received limited attention.
                Bookmark

                Author and article information

                Contributors
                e.f.blom@erasmusmc.nl
                Journal
                Cancer
                Cancer
                10.1002/(ISSN)1097-0142
                CNCR
                Cancer
                John Wiley and Sons Inc. (Hoboken )
                0008-543X
                1097-0142
                27 February 2019
                15 June 2019
                : 125
                : 12 ( doiID: 10.1111/cncr.2019.125.issue-12 )
                : 2039-2048
                Affiliations
                [ 1 ] Department of Public Health Erasmus MC University Medical Center Rotterdam Rotterdam the Netherlands
                [ 2 ] Division of Pulmonary & Critical Care Medicine University of Michigan Ann Arbor Michigan
                Author notes
                [*] [* ] Corresponding author: Erik F. Blom, MD, Department of Public Health, Erasmus MC University Medical Center Rotterdam, P.O. Box 2040, Internal Postal Address Na‐2401, 3000CA Rotterdam, the Netherlands; e.f.blom@ 123456erasmusmc.nl

                Author information
                https://orcid.org/0000-0002-2016-5668
                Article
                CNCR32026
                10.1002/cncr.32026
                6541509
                30811590
                a5fb61e7-566d-45b3-bc62-43542e20fc14
                © 2019 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 27 August 2018
                : 10 January 2019
                : 29 January 2019
                Page count
                Figures: 5, Tables: 0, Pages: 10, Words: 11840
                Funding
                Funded by: National Cancer Institute
                Award ID: 1U01CA199284-01
                Categories
                Original Article
                Original Articles
                Discipline
                Cancer Prevention
                Custom metadata
                2.0
                cncr32026
                June 15, 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.4 mode:remove_FC converted:13.06.2019

                Oncology & Radiotherapy
                early detection of cancer,health resources,health workforce,lung neoplasms,therapy

                Comments

                Comment on this article